Production and characterization of scFvA33T1, an immunoRNase targeting colon cancer cells

FEBS Journal

Volumn 279, Issue 17, 2012, Pages 3022-3032

  Tomé Amat, Jaime ^a   Menéndez Méndez, Aida ^a   García Ortega, Lucía ^a   Batt, Carl A ^b   Oñaderra, Mercedes ^a   Martínez Del Pozo, Álvaro ^a   Gavilanes, José G ^a   Lacadena, Javier ^a  

^a UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^b Department of Obstetrics Gynecology   (United States)

Author keywords

colon cancer; GPA33; immunoRNase; RNase T1; scFvA33

Indexed keywords

GLYCOPROTEIN A33 ANTIGEN; MEMBRANE ANTIGEN; RIBONUCLEASE T1; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; UNCLASSIFIED DRUG;

ANTIGEN SPECIFICITY; ARTICLE; CANCER CELL CULTURE; COLON CANCER; CONTROLLED STUDY; DRUG BINDING; DRUG CYTOTOXICITY; DRUG SYNTHESIS; DRUG TARGETING; HUMAN; HUMAN CELL; INTERNALIZATION; PICHIA PASTORIS; PRIORITY JOURNAL; PROTEIN FOLDING; PROTEIN PURIFICATION;

CIRCULAR DICHROISM; COLONIC NEOPLASMS; ELECTROPHORESIS, POLYACRYLAMIDE GEL; ENDOCYTOSIS; HUMANS; RIBONUCLEASE T1; SINGLE-CHAIN ANTIBODIES; SPECTROPHOTOMETRY, ULTRAVIOLET;

PICHIA PASTORIS;

EID: 84865216183     PISSN: 1742464X     EISSN: 17424658     Source Type: Journal    
DOI: 10.1111/j.1742-4658.2012.08683.x     Document Type: Article

References (46)

1. Adams GP, &, Weiner LM, (2005) Monoclonal antibody therapy of cancer. Nat Biotechnol 23, 1147-1157.
2. Dougan M, &, Dranoff G, (2009) Immune therapy for cancer. Annu Rev Immunol 27, 83-117.
3. Kreitman RJ, (2009) Recombinant immunotoxins containing truncated bacterial toxins for the treatment of hematologic malignancies. BioDrugs 23, 1-13.
4. Pastan I, Hassan R, FitzGerald DJ, &, Kreitman RJ, (2007) Immunotoxin treatment of cancer. Annu Rev Med 58, 221-237.
5. Holzman DC, (2009) Whatever happened to immunotoxins? Research and hope are still alive. J Natl Cancer Inst 101, 624-625.
6. Carreras-Sangrá N, Alvarez-García E, Herrero-Galán E, Tomé J, Lacadena J, Alegre-Cebollada J, Oñaderra M, Gavilanes JG, &, Martínez-Del-Pozo A, (2008) The therapeutic potential of fungal ribotoxins. Curr Pharm Biotechnol 9, 153-160.
7. Rybak SM, Arndt MA, Schirrmann T, Dübel S, &, Krauss J, (2009) Ribonucleases and immunoRNases as anticancer drugs. Curr Pharm Des 15, 2665-2675.
8. Schirrmann T, Krauss J, Arndt MAE, Rybak SM, &, Dubel S, (2009) Targeted therapeutic RNases (immunoRNases). Expert Opin Biol Ther 9, 79-95.
9. Ardelt W, Ardelt B, &, Darzynkiewicz Z, (2009) Ribonucleases as potential modalities in anticancer therapy. Eur J Pharmacol 625, 181-189.
10. De Lorenzo C, &, D'Alessio G, (2009) Human anti-ErbB2 immunoagents-immunoRNases and compact antibodies. FEBS J 276, 1527-1535.
11. Edelweiss E, Balandin TG, Ivanova JL, Lutsenko GV, Leonova OG, Popenko VI, Sapozhnikov AM, &, Deyev SM, (2008) Barnase as a new therapeutic agent triggering apoptosis in human cancer cells. PLoS One 3, e2434.
12. Shlyakhovenko VA, (2009) Ribonucleases in tumor growth. Exp Oncol 31, 127-133.
13. Heath JK, White SJ, Johnstone CN, Catimel B, Simpson RJ, Moritz RL, Tu GF, Ji H, Whitehead RH, Groenen LC, et al. (1997) The human A33 antigen is a transmembrane glycoprotein and a novel member of the immunoglobulin superfamily. Proc Natl Acad Sci USA 94, 469-474.
14. Ackerman ME, Chalouni C, Schmidt MM, Raman VV, Ritter G, Old LJ, Mellman I, &, Wittrup KD, (2008) A33 antigen displays persistent surface expression. Cancer Immunol Immunother 57, 1017-1027.
15. Scott AM, Lee FT, Jones R, Hopkins W, MacGregor D, Cebon JS, Hannah A, Chong GUP, Papenfuss A, Rigopoulos A, et al. (2005) A phase I trial of humanized monoclonal antibody A33 in patients with colorectal carcinoma: biodistribution, pharmacokinetics, and quantitative tumor uptake. Clin Cancer Res 11, 4810-4817.
16. King DJ, Antoniw P, Owens RJ, Adair JR, Haines AM, Farnsworth AP, Finney H, Lawson AD, Lyons A, Baker TS, et al. (1995) Preparation and preclinical evaluation of humanised A33 immunoconjugates for radioimmunotherapy. Br J Cancer 72, 1364-1372.
17. Ritter G, Cohen LS, Williams CJR, Richards EC, Old LJ, &, Welt S, (2001) Serological analysis of human anti-human antibody responses in colon cancer patients treated with repeated doses of humanized monoclonal antibody A33. Cancer Res 61, 6851-6859.
18. Damasceno LM, Pla I, Chaung HJ, Cohen L, Ritter G, Old L, &, Batt CA, (2004) An optimized fermentation process for high-level production of a single-chain Fv antibody fragment in Pichia pastoris. Protein Expr Purif 37, 18-26.
19. Damasceno LM, Lee F, Ritter G, Old L, &, Batt C, (2009) High-level expression of a phage display-derived scFv in Pichia pastoris. Methods Mol Biol 562, 225-236.
20. Steyaert J, (1997) A decade of protein engineering on ribonuclease T1-atomic dissection of the enzyme-substrate interactions. Eur J Biochem 247, 1-11.
21. Yoshida H, (2001) The ribonuclease T1 family. Methods Enzymol 341, 28-41.
22. Uchida T, (1970) Inmunochemical properties of ribonuclease T1 in relation to other ribonucleases. J Biochem 68, 255-264.
23. Balandin TG, Edelweiss E, Andronova NV, Treshalina EM, Sapozhnikov AM, &, Deyev SM, (2011) Antitumor activity and toxicity of anti-HER2 immunoRNase scFv 4D5-dibarnase in mice bearing human breast cancer xenografts. Invest New Drugs 29, 22-32.
24. Yuki S, Kondo Y, Kato F, Kato M, &, Matsuo N, (2004) Noncytotoxic ribonuclease, RNase T1, induces tumor cell death via hemagglutinating virus of Japan envelope vector. Eur J Biochem 271, 3567-3572.
25. Center MM, Jemal A, Smith RA, &, Ward E, (2009) Worldwide variations in colorectal cancer. CA Cancer J Clin 59, 366-378.
26. Enever C, Batuwangala T, Plummer C, &, Sepp A, (2009) Next generation immunotherapeutics-honing the magic bullet. Cur Opin Biotechnol 20, 405-411.
27. Chong G, Lee FT, Hopkins W, Tebbutt N, Cebon JS, Mountain AJ, Chappell B, Papenfuss A, Schleyer PUP, Murphy R, et al. (2005) Phase I trial of 131I-huA33 in patients with advanced colorectal carcinoma. Clin Cancer Res 11, 4818-4826.
28. Welt S, Ritter G, Williams C Jr, Cohen LS, John M, Jungbluth A, Richards EA, Old LJ, &, Kemeny NE, (2003) Phase I study of anticolon cancer humanized antibody A33. Clin Cancer Res 9, 1338-1346.
29. Carmichael JA, Power BE, Garrett TPJ, Yazaki PJ, Shively JE, Raubischek AA, Wu AM, &, Hudson PJ, (2003) The crystal structure of an anti-CEA scFv diabody assembled from T84.66 scFvs in V(L)-to-V(H) orientation: implications for diabody flexibility. J Mol Biol 326, 341-351.
30. Pace CN, Heinemann U, Hahn U, &, Saenger W, (1991) Ribonuclease T1: structure, function and stability. Angew Chem Int Ed Engl 30, 343-454.
31. Wilkinson IC, Hall CJ, Veverka V, Shi JY, Muskett FW, Stephens PE, Taylor RJ, Henry AJ, &, Carr MD, (2009) High Resolution NMR-based model for the structure of a scFv-IL-1β complex. J Biol Chem 284, 31928-31935.
32. Daghighian F, Barendswaard E, Welt S, Humm J, Scott A, Willingham MC, McGuffie E, Lloyd JO, &, Larson SM, (1996) Enhancement of radiation dose to the nucleus by vesicular internalization of iodine-125-labelled A33 monoclonal antibody. J Nucl Med 37, 1052-1057.
33. Goyal A, &, Batra JK, (2000) Inclusion of a furin-sensitive spacer enhances the cytotoxicity of ribotoxina restrictocin containing recombinant single-chain immunotoxin. Biochem J 345, 247-254.
34. Deckert PM, Renner C, Cohen LS, Jungbluth A, Ritter G, Bertino JR, Old LJ, &, Welt S, (2003) A33scFv-cytosine deaminase: a recombinant protein construct for antibody-directed enzyme-prodrug therapy. Br J Cancer 88, 937-939.
35. Kirui DK, Rey DA, &, Batt CA, (2010) Gold hybrid nanoparticles for targeted phototherapy and cancer imaging. Nanotechnology 21, 105-115.
36. Shirley BA, &, Laurents DV, (1990) Purification of recombinant ribonuclease T1 expressed in Escherichia coli. J Biochem Biophys Methods 20, 181-188.
37. Martínez-Ruiz A, Martínez-del-Pozo A, Lacadena J, Mancheño JM, Oñaderra M, López-Otín C, &, Gavilanes JG, (1998) Secretion of recombinant pro- and mature fungal α-sarcin ribotoxin by the methylotrophic yeast Pichia pastoris: the Lys-Arg motif is required for maturation. Protein Expr Purif 12, 315-322.
38. López-García B, Moreno AB, San Segundo B, De los Ríos V, Manning JM, Gavilanes JG, &, Martínez-del-Pozo A, (2010) Production of the biotechnologically relevant AFP from Aspergillus giganteus in the yeast Pichia pastoris. Protein Expr Purif 70, 206-210.
39. Gasset M, Oñaderra M, Goormaghtigh E, &, Gavilanes JG, (1991) Acid phospholipid vesicles produce conformational changes on the antitumor protein α-sarcin. Biochim Biophys Acta 1080, 51-58.
40. Lacadena J, Martínez-del-Pozo A, Martínez-Ruiz A, Pérez-Cañadillas JM, Bruix M, Mancheño JM, Oñaderra M, &, Gavilanes JG, (1999) Role of histidine-50, glutamic acid-96, and histidine-137 in the ribonucleolytic mechanism of the ribotoxin α-sarcin. Proteins 37, 474-484.
41. 2-terminal β-hairpin of the ribotoxin α-sarcin produces a nontoxic but active ribonuclease. J Biol Chem 277, 18632-18639.
42. Herrero-Galán E, Lacadena J, Martínez-del-Pozo A, Boucias DG, Olmo N, Oñaderra M, &, Gavilanes JG, (2008) The insecticidal protein hirsutellin A from the mite fungal pathogen Hirsutella thompsonii is a ribotoxin. Proteins 72, 217-228.
43. Olmo N, Turnay J, González de Buitrago G, López de Silanes I, Gavilanes JG, &, Lizarbe MA, (2001) Cytotoxic mechanism of the ribotoxin α-sarcin. Induction of cell death via apoptosis. Eur J Biochem 268, 2113-2123.
44. Turnay J, Olmo N, Jiménez A, Lizarbe MA, &, Gavilanes JG, (1993) Kinetic study of the cytotoxic effect of α-sarcin, a ribosome inactivating protein from Aspergillus giganteus, on tumor cell lines: protein biosynthesis inhibition and cell binding. Mol Cell Biochem 122, 39-47.
45. Martínez-Ruiz A, García-Ortega L, Kao R, Lacadena J, Oñaderra M, Mancheño JM, Davies J, Martínez del Pozo A, &, Gavilanes JG, (2001) RNase U2 and α-sarcin: a study of relationships. Methods Enzymol 341, 335-351.
46. Yeung TM, Shaan CG, Wilding JL, Muschel R, &, Bodmer WF, (2009) Cancer stem cells from colorectal cancer-derived cell lines. Proc Natl Acad Sci USA 107, 3722-3727.